Morgan Stanley upgraded Nurix Therapeutics (NRIX) to Overweight from Equal Weight with a price target of $36, up from $15. The firm sees a higher probability of success for bexobrutideg and chronic lymphocytic leukemia. In addition, Nurix has “building pipeline optionality” with STAT6 and IRAK4 degraders entering the clinic, the analyst tells investors in a research note.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NRIX:
- Nurix Therapeutics Advances Study for NX-5948 in CLL and SLL Patients
- HOOD, IBTA, IRDM: Cathie Wood Buys the Dip in Robinhood, Sells Ibotta and Iridium Stocks
- Cathie Wood Capitalizes the Surge in Iridium and Biotech Stocks
- Nurix Therapeutics price target raised to $30 from $24 at Mizuho
- Nurix Therapeutics price target raised to $31 from $28 at H.C. Wainwright